Arbor Biotechnologies
Business Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
20 Acorn Park Dr Ste 500, Cambridge, Mas...Phone Number
(857) 301-6366Website
arbor.bioRevenue
$39.7 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
2
1
1
1
About Arbor Biotechnologies
Arbor Biotechnologies, a next-generation gene editing company based in Cambridge, MA, is advancing a pipeline of novel gene editing therapeutics to address a wide range of genetic conditions from the ultra-rare to the most common genetic diseases. The companys unique suite of optimized gene editors, which is capable of approaches ranging from gene knockout, excisions, reverse transcriptase editing, and large gene insertion, goes beyond the limitations of early editing technologies to unlock access to new gene targets and has fueled a robust pipeline of first-in-class assets focused on diseases of high unmet need. With Arbors lead program, ABO-101 for the treatment of primary hyperoxaluria type 1, in clinical development, the company continues to focus their research and development efforts on genomic diseases of the liver and CNS for which there are no existing functional cures.Explore more
Arbor Biotechnologies Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Arbor Biotechnologies your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Arbor Biotechnologies has new funding data
Congratulate Masked Content for being promoted to Masked Content at Arbor Biotechnologies
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Arbor Biotechnologies launches new products
Arbor Biotechnologies, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Arbor Biotechnologies recently announced quarterly report
Check if Arbor Biotechnologies has recently received funding, and reach out quickly before it becomes old news!
Click to see if Arbor Biotechnologies had a recent Job posting/layoffs
Check out if Arbor Biotechnologies is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Arbor Biotechnologies
Compare insights from companies similar to Arbor Biotechnologies, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$19.3M
51-200
Private
-
2008
TS
Trushant ShahNeo Wealth & Asset Management Vice President, Corporate Strategy
Company Profile Activity
Activity Insights
Arbor Biotechnologies is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Arbor Biotechnologies is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Arbor Biotechnologies.
Arbor Biotechnologies financials insights
Gather financial insights about Arbor Biotechnologies, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$350K
2021
Series B
$215M
2025
Series C
$73.9M
Arbor Biotechnologies Tech Stack
A closer look at the technologies used by Arbor Biotechnologies
See more technologies
Most Recent Scoops
Person-Based
Partnership, Medical Research
Open Position
New Hire
Executive Move
Executive Moves, New Hire
Open Position
Open Position
Arbor Biotechnologies News & Media
Arbor Biotechnologies Appoints Mathew Pletcher, Ph.D., as Chief Scientific Officer
Gene therapy and rare disease leader with nearly two decades of drug development experience to focus on advancing the company’s next-generation gene editing pipeline Gene therapy and rare disease leader with nearly two decades of drug development experience to focus on advancing the company’s next-generation gene editing pipelineArbor Biotechnologies Achieves Unprecedented Precise In Vivo Reverse Transcriptase Editing in the Brain Using a Single AAV Vector, Opening a New Path to Treatments for Neurological Diseases
- Oral presentation at ASGCT showcases breakthrough technology enabling precise in vivo genome editing in the CNS using a single AAV vector - Two poster presentations describe methods that support accelerated development of Arbor’s proprietary gene editing platformArbor Biotechnologies to Present Expansion of CNS Editing Platform Capabilities at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting
- Oral presentation highlights novel compact RT editor demonstrating first preclinical in vivo proof of concept for precise gene editing in the CNS delivered via a single AAVChiesi Group and Arbor Biotechnologies Announce a Global Strategic Partnership to Develop Novel Rare Disease Gene Editing Programmes
PARMA, Italy and CAMBRIDGE, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Chiesi Group, an international research-oriented biopharmaceutical company, together with Arbor Biotechnologies, Inc., a next-generation biotechnology company discovering and developing innovative approaches in genetic medicines, today announced an exclusive global collaboration and license agreement for Arbor’s clinical stage programme ABO-101 in PH1 together with a multitarget option agreement for the use of Arbor’s advanced
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Arbor Biotechnologies
Sign Up For FreeTo access detailed company insights
Arbor Biotechnologies, a next-generation gene editing company based in Cambridge, MA, is advancing a pipeline of novel gene editing therapeutics to address a wide range of genetic conditions from the ultra-rare to the most common genetic diseases. The companys unique suite of optimized gene editors, which is capable of approaches ranging from gene... Read More
